Residency · Residency · Pathology

Laboratory Accreditation, CLIA, and Quality Management Systems

Introduction

Laboratory quality is governed by a framework of federal regulations, accreditation standards, and quality management systems. Understanding these requirements is fundamental for pathologists who direct and oversee clinical laboratories, ensuring that testing is accurate, reliable, and compliant with regulatory mandates.

Clinical Laboratory Improvement Amendments (CLIA)

Overview

CLIA '88 is the federal law establishing quality standards for all laboratory testing performed on human specimens in the United States. It is administered by the Centers for Medicare & Medicaid Services (CMS) and applies to approximately 260,000+ laboratory entities. Any facility performing testing on human specimens for diagnosis, prevention, or treatment must hold a CLIA certificate.

Test Complexity Categories

Waived tests are simple procedures with minimal risk of error, such as urine dipstick, rapid strep, and glucose meters. They require a certificate of waiver and must follow manufacturer instructions. Moderate complexity tests encompass most routine laboratory testing, including automated chemistry and hematology analyzers. High complexity tests require significant technical skill and judgment, including manual differentials, flow cytometry, histopathology, molecular testing, and cytogenetics. Classification is determined by CMS based on scoring of seven criteria including training, reagent preparation, operational steps, and interpretation.

CLIA Requirements for Non-Waived Testing

Personnel qualifications mandate a laboratory director (MD/DO with board certification), technical supervisor, clinical consultant, general supervisor, and testing personnel. Quality control (QC) requires a minimum of two levels of control per day (or per run) for quantitative tests, with equivalent QC through an Individualized Quality Control Plan (IQCP) allowed for certain tests. Proficiency testing (PT) requires enrollment in CMS-approved PT programs with successful performance for each regulated analyte. Quality assessment involves ongoing monitoring of pre-analytical, analytical, and post-analytical processes. Patient test management covers procedures for specimen handling, test requisitions, result reporting, and record retention.

Individualized Quality Control Plan (IQCP)

IQCP is a risk-based alternative to traditional QC frequency. It begins with a risk assessment of pre-analytical, analytical, and post-analytical phases. A customized QC plan is developed based on identified risks, and the plan's effectiveness is monitored and evaluated through quality indicators. IQCP is not applicable to all test systems, and waived tests and PT-regulated analytes have specific requirements.

Accreditation Organizations

College of American Pathologists (CAP)

CAP is the largest accrediting body for clinical laboratories and holds deemed status from CMS, meaning that a CAP inspection satisfies CLIA requirements. Peer-based inspections are conducted every two years by teams of laboratory professionals. Inspections are checklist-based, covering all laboratory sections including chemistry, hematology, microbiology, blood bank, anatomic pathology, molecular, and point-of-care testing. PT requirements are integrated into accreditation, and CAP Surveys are widely used. The checklists are updated regularly with evidence-based requirements.

The Joint Commission (TJC)

TJC accredits hospitals and health systems and includes laboratory standards. It holds deemed status for CLIA and evaluates the laboratory as part of hospital-wide accreditation, with a focus on patient safety, quality improvement, and organizational performance.

AABB (Formerly American Association of Blood Banks)

AABB accredits blood banks and transfusion services, with standards addressing blood collection, processing, storage, compatibility testing, and transfusion. Biennial assessment complements CAP or TJC accreditation for transfusion medicine.

Other Accrediting Bodies

COLA (Commission on Laboratory Accreditation) focuses on physician office laboratories. ASHI (American Society for Histocompatibility and Immunogenetics) accredits HLA laboratories. Some states, including New York and California, have additional state licensure requirements that exceed CLIA.

Quality Management Systems

Quality Management System Framework

ISO 15189 is the international standard for medical laboratory quality and competence. Twelve quality system essentials (QSEs) are defined by CLSI (Clinical and Laboratory Standards Institute): (1) Organization, (2) Personnel, (3) Equipment, (4) Purchasing and inventory, (5) Process control (QC), (6) Information management, (7) Documents and records, (8) Occurrence management (nonconformances), (9) Assessment (internal audits, external audits), (10) Continual improvement, (11) Customer service, and (12) Facilities and safety.

Key Quality Indicators

Pre-analytical indicators include specimen rejection rate, patient identification errors, order accuracy, and transport time. Analytical indicators encompass QC performance, proficiency testing scores, calibration verification, and correlation studies. Post-analytical indicators include turnaround time, critical value notification compliance, amended report rate, and result accuracy.

Document Control

All standard operating procedures (SOPs) must be current, reviewed annually, and accessible to testing personnel. Version control with documented review and approval is required, and controlled distribution ensures that retired documents are archived. Training documentation must be linked to each SOP.

Proficiency Testing

Requirements

Proficiency testing is mandatory for all non-waived testing, with participation in CMS-approved programs required. The minimum requirement is three testing events per year with five samples per event for regulated analytes. Results are graded against peer group or defined criteria. Unsuccessful performance on two consecutive or two of three events triggers investigation, corrective action, and potential sanctions. Referral of PT samples between laboratories is prohibited and constitutes fraud.

Corrective Action for PT Failures

The response to a PT failure involves root cause analysis of the failure, documentation of the corrective action plan and its implementation, verification that the corrective action is effective, and reporting to the laboratory director and quality committee. Repeat testing may be required, and CMS sanctions for continued failures include suspension of testing.

Test Validation and Verification

Verification of FDA-Cleared/Approved Tests

Verification confirms that a test performs as expected in the laboratory's own environment. It requires demonstrating accuracy, precision, reportable range, and reference interval applicability. Results are compared with manufacturer claims and peer laboratory data. Verification is less extensive than full validation and is appropriate for unmodified FDA-cleared tests.

Validation of Laboratory-Developed Tests (LDTs)

Validation is a comprehensive establishment of performance characteristics. Required parameters include analytical sensitivity, analytical specificity, accuracy, precision, reportable range, reference intervals, and interfering substances. For molecular tests, additional parameters include limit of detection and reproducibility across operators and runs. LDTs are developed and used within a single laboratory and are not FDA-cleared. Ongoing regulatory discussions continue regarding FDA oversight of LDTs.

Clinical Pearls

All laboratories performing testing on human specimens in the United States must hold a CLIA certificate, and test complexity classification determines the level of regulatory requirements applied. CAP accreditation provides deemed status satisfying CLIA inspection requirements and is the most widely used peer-based accreditation program for clinical laboratories. Proficiency testing is mandatory for all non-waived analytes, and referral of PT samples between laboratories is prohibited and constitutes regulatory fraud. Laboratory-developed tests require comprehensive validation establishing all performance characteristics, as they are not subject to FDA pre-market review under current regulatory frameworks.

References

1. Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments (CLIA). Available at: https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA.
2. College of American Pathologists. Laboratory Accreditation Program. Available at: https://www.cap.org/laboratory-improvement/accreditation.
3. CLSI. Quality Management System: A Model for Laboratory Services. QMS01-Ed5. Clinical and Laboratory Standards Institute; 2019.
4. Genzen JR, et al. Regulation of laboratory-developed tests: current state and future considerations. Clin Chem. 2022;68(12):1568-1576.

Read this lecture as Markdown